
212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy
The Readout Loud
00:00
What's the Biggest Loser Coming Out of Ascoare?
Gilead sciences has been in the news at cancer conferences for years. The company is trying to become a player in developing cancer treatment that might have practice changing data like you just described. Adam: Biggest loser coming out of asco from a corporate perspective was gilead Sciences. He says there's even a discussion, i think, that tordelvi could encroach into metastatic triple negative breast cancer.
Transcript
Play full episode